Olumiant Shortage Update: What Patients Need to Know in 2026

If you rely on Olumiant (baricitinib) for rheumatoid arthritis, alopecia areata, or COVID-19 treatment, you want a clear answer: can I actually get my medication right now? This article gives you the 2026 update on Olumiant availability — what the FDA says, what patients are experiencing, and what you can do if you're having trouble.

Is Olumiant in Shortage Right Now?

As of early 2026, Olumiant (baricitinib) is NOT listed on the FDA drug shortage database. This means the FDA considers the overall supply of Olumiant adequate to meet national demand. Eli Lilly, the sole manufacturer, reports stable production.

However — and this is important — "not in shortage" does not mean "easy to access." Olumiant is a limited-distribution specialty medication, and patients regularly report difficulty getting it filled. This is a system-level access problem, not a manufacturing shortage.

The History: When Did Olumiant Have Supply Problems?

Olumiant experienced its most significant supply disruptions in 2020 and 2021. When the FDA granted Emergency Use Authorization for baricitinib to treat COVID-19 in hospitalized patients, demand for the drug surged dramatically. Hospitals and health systems competed for available supply alongside the existing rheumatoid arthritis patient population. This created real shortfalls in 2020–2021.

Since receiving full FDA approval in May 2022 for COVID-19 treatment and June 2022 for alopecia areata, Eli Lilly has adjusted production capacity. Supply has stabilized since late 2022 and has remained stable through 2025 and into 2026.

Why Are Patients Still Having Trouble Getting Olumiant?

Even without an active shortage, patients face real barriers to getting Olumiant. The most common reasons include:

Specialty-pharmacy-only distribution: Olumiant cannot be filled at standard retail pharmacies. Only designated specialty pharmacies carry it.

Insurance prior authorization: Most insurance plans require prior authorization (and often step therapy) before they'll cover Olumiant. This process can delay access by 5–14 days or more.

High cost without insurance: At $2,500–$3,000 per month without insurance, many patients without coverage can't afford it without assistance programs.

No generic available: As of 2026, no generic baricitinib exists in the U.S. market. Every patient must go through Eli Lilly's branded Olumiant and its specialty pharmacy network.

Inventory variability by dose: Individual specialty pharmacies may have limited stock of specific tablet strengths (1 mg, 2 mg, or 4 mg) at any given time.

What About the Olumiant Shortage During COVID-19?

The 2020–2021 Olumiant supply strain is largely resolved. COVID-19 hospitalization rates have declined significantly from pandemic peaks, reducing hospital demand for baricitinib. Eli Lilly has stated that manufacturing capacity was adjusted to meet expanded demand across all three approved indications. RA patients who struggled to find their medication during the COVID-19 surge should find access more predictable now — with the main barriers being insurance and specialty pharmacy logistics, not manufacturing supply.

When Will a Generic Olumiant Be Available?

Patent protections for Olumiant extend through the mid-to-late 2020s. As of 2026, no generic baricitinib has been approved in the United States. When a generic does become available, it could significantly increase availability and reduce cost. Watch for FDA approvals in the coming years — this will be a significant milestone for patients.

What Should You Do If You Can't Get Olumiant Right Now?

Search for available specialty pharmacies: Use medfinder.com to find which pharmacies near you can fill your prescription.

Contact Eli Lilly at 1-800-545-5979: Lilly Support Services can help connect you with available supply and patient assistance programs.

Call your insurance plan: Ask which in-network specialty pharmacy has Olumiant in stock and confirm your prior authorization status.

Contact your prescriber: Rheumatology and dermatology offices often have direct relationships with specialty pharmacies and can expedite your access.

Ask about alternatives: If Olumiant truly isn't accessible, talk to your doctor about alternative JAK inhibitors — see our guide on Olumiant alternatives.

The Bottom Line

Olumiant is not in a national FDA-recognized shortage in 2026. But specialty medication access remains genuinely complicated, and individual patients can still face real difficulty filling their prescriptions. Understanding the system — and knowing where to get help — is your best tool. For a complete list of fallback options, read our guide to alternatives to Olumiant.